Direct medical and non-medical costs of a one-year care pathway for early breast cancer: results of a French multicenter prospective study (original) (raw)
Related papers
The costs of breast cancer prior to and following diagnosis
European Journal of Health Economics, 2011
This retrospective incidence-based cost-of-illness analysis aims to quantify the costs associated with female breast cancer in Flanders for the year prior to diagnosis and for each of the 5 years following diagnosis. A bottom-up analysis from the societal perspective included direct health care costs and indirect costs of productivity loss due to morbidity and premature mortality. A case-control study design compared total costs of breast cancer patients with costs of an equivalent standardised population with a view to calculating the additional costs that can be attributed to breast cancer. Total average costs of breast cancer amounted to 107,456 € per patient over 6 years. Total costs consisted of productivity loss costs (89% of costs) and health care costs (11% of costs). Health care costs did not vary with age at diagnosis. Health care costs of breast cancer patients converged with those of the general population at 5 years following diagnosis. Patients with advanced breast cancer stadia had higher health care costs. Cost estimates provided by this analysis can be used to determine priorities for, and inform, future research on breast cancer. In particular, attention needs to be focussed on decreasing productivity loss from breast cancer.
Health system costs for stage-specific breast cancer: a population-based approach
The objective of the present analysis was to determine the publicly funded health care costs associated with the care of breast cancer (bca) patients by disease stage. Incident cases of female invasive bca (2005-2009) were extracted from the Ontario Cancer Registry and linked to administrative datasets from the publicly funded system. The type and use of health care services were stratified by disease stage over the first 2 years after diagnosis. Mean costs and costs by type of clinical resource used in the care of bca patients were compared with costs for a matched control group. The attributable cost for the 2-year time horizon was determined in 2008 Canadian dollars. This cohort study involved 39,655 patients with bca and 190,520 control subjects. The average age in those groups was 61.1 and 60.9 years respectively. Most bca patients were classified as either stage i (34.4%) or stage ii (31.8%). Of the bca cohort, 8% died within the first 2 years after diagnosis. The overall mean...
The patient-breast cancer care pathway: how could it be optimized?
BMC Cancer, 2015
Background: A care pathway is defined as patient-focused global care that addresses temporal (effective and coordinated management throughout the illness) and spatial issues (treatment is provided near the health territory in or around the patient's home). Heterogeneity of the care pathways in breast cancer (BC) is presumed but not well evaluated. The OPTISOINS01 study aims to assess every aspect of the care pathway for early BC patients using a temporal and spatial scope.
BMJ Open, 2020
ObjectivesUsing a standardised diagnostic and generic treatment path for breast cancer, and the molecular subtype perspective, we aim to measure the impact of several patient and disease characteristics on the overall treatment cost for patients. Additionally, we aim to generate insights into the drivers of cost variability within one medical domain.Design, setting and participantsWe conducted a retrospective study at a breast clinic in Belgium. We used 14 anonymous patient files for conducting our analysis.ResultsSignificant cost variations within each molecular subtype and across molecular subtypes were found. For the luminal A classification, the cost differential amounts to roughly 166%, with the greatest treatment cost amounting to US$29 780 relative to US$11 208 for a patient requiring fewer medical activities. The major driver for these cost variations relates to disease characteristics. For the luminal B classification, a cost difference of roughly 242% exists due to both di...
Indirect costs in patients with breast cancer: protocol for a systematic review
2020
Background:The rising incidence of breast cancer places a financial burden on national health services and economies. The cost of breast cancer studies is constantly increasing; however, this cost is calculated based on the currency of the country in which the study takes place, therefore limiting national and international comparisons. On the other hand, there is no common method used to conduct such studies. The objective of this review is to contribute to this knowledge pool by examining the indirect costs of breast cancer in order to provide comparable estimates.Methods and analysis:This review will consider all relevant cost of illness studies dated from the year 2000 until the year 2018. Relevant papers will be identified through a systematic search in all major medical research databases. Two independent researchers will screen selected articles. Methodological quality of the studies will be assessed using a checklist designed by Stunhldreher et al. Discussion:The results wil...
Cost of breast cancer based on real-world data: a cancer registry study in Italy
Background: In European countries, it is difficult for local health organizations to determine the resources allocated to different hospitals for breast cancer. The aim of the current study was to examine the costs of breast cancer during the different phases of the diagnostictherapeutic sequence based on real world data.
Annals of Oncology, 1995
This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Intensive versus minimum surveillance follow-up protocols after primary treatment of breast cancer. The 'intensive' strategy was defined as that including physician visits with bone scans, liver echocardiography, chest roentgenography, and laboratory tests being performed at predetermined intervals. The 'minimum' strategy involved the physician visits at the same frequency but performing clinically indicated tests only. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Italian women younger than 70 years with non-inflammatory, unilateral primary breast cancer (stage I, II, and III) undergoing surgery.
Influence of surgical and treatment choices on the cost of breast cancer care
The European Journal of Health Economics, 2003
We obtained medical claim files covering a period of 1 year prior to breast cancer diagnosis and the year following diagnosis for 204 women and estimated the cost of their treatment.We used log-linear regression controlling for age, comorbidity, physical functioning, and disease stage.To retransform the mean costs, we estimated separate smearing factors for surgical and adjuvant care types.The adjusted mean costs for breast cancer care ranged from 16,226to16,226 to 16,226to39,305 depending on the treatment provided with mastectomy being the least expensive option.Breast-conserving surgery (BCS) was more expensive because most women have multiple surgeries after the initial BCS and require adjuvant care.If the first surgery was a mastectomy, medical care use tends to return to precancer spending levels within a few months.Over one-half of the women in this study had multiple surgeries following diagnosis, leading to substantial costs and unknown morbidity.
Cost analysis of breast cancer: a comparison between private and public hospitals in Iran
2021
Backgrounds Breast cancer is the most prevalent cancer among women. Breast cancer imposes a considerable economic burden on the health system. This study aimed to compare the cost of breast cancer among patients who referred to private and public hospitals in Iran (2017). Methods This was a prevalence-based cost of illness study. A total of 179 patients were selected from private and public hospitals using the census method. The researcher-constructed checklist was used for data collection. Data were analyzed using SPSS software version 22. Results The estimated total mean (SD) direct cost of patients who referred to the private hospital and the public hospital was 10,050(19,480)and10,050 (19,480) and 10,050(19,480)and3960 (6780), respectively. Further, the total mean indirect cost of patients who referred to the private hospital was lower than those referring to the public hospital at 1870(151870 (15 % of total costs) and 1870(1522,350 (85 % of total costs), respectively. These differences were statistically significant ( P ...